Idiopathic Pulmonary Fibrosis – Landscape & Forecast – Disease Landscape & Forecast
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT) approved for IPF, followed soon after by Boehringer Ingelheim’s nintedanib (Ofev). These therapies set the stage for fierce competition in the IPF therapy market. We explore this evolving space by examining the current medical practice, including the clinical and commercial outlook for pirfenidone and nintedanib; identifying the areas of pressing unmet need in the treatment of IPF; and assessing emerging therapies, including United Therapeutics’ inhaled treprostinil and Boehringer Ingelheim's PO-administered BI-1015550.
Questions answered
- How will the size of the IPF population change through 2032? How large are the key subpopulations? What percentage of the IPF population receives drug treatment?
- How do interviewed experts view the clinical profiles of Esbriet and Ofev, and what factors drive or constrain their use? What are the most pressing clinical needs in the management of IPF, according to experts?
- Which emerging therapies do IPF experts consider most promising? If approved, how would emerging therapies influence the management of IPF and the market positions of Ofev and Esbriet? What is the commercial potential of inhaled treprostinil and BI-1015550?
Product description
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Idiopathic Pulmonary Fibrosis - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Idiopathic Pulmonary Fibrosis - Key Findings
- Commercial Outlook
- Key findings
- Regional sales of key therapies to treat IPF: 2022 and 2032
- IPF SWOT analysis
- Drivers and constraints
- What factors are driving the market for IPF?
- What factors are constraining the market for IPF?
- Drug-class-specific trends
- Antifibrotics
- Tyrosine kinase inhibitors
- Prostacyclin vasodilators
- Phosphodiesterase 4B inhibitors
- Key findings
- Forecast
- Sales of key therapies in idiopathic pulmonary fibrosis
- Etiology and Pathophysiology
- Disease overview
- Etiology
- Key risk factors associated with idiopathic pulmonary fibrosis
- The lung in IPF
- Pathophysiology
- Role of inflammation
- Pathogenesis of IPF
- Disease progression
- Characteristics of rapid, moderate, and slow progressors
- Disease staging
- The GAP index
- Symptoms and complications
- Symptoms and complications of IPF
- Key symptoms and complications of IPF
- Key pathways and drug targets
- Key pathways and drug targets in IPF
- Key pathways and drug targets in IPF
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods and sources used for prevalence of IPF
- Diagnosed prevalent cases of IPF: 2022-2032
- Disease definition
- Methods and sources used for severity stages of IPF
- Diagnosed prevalent cases of IPF by GAP severity: 2022-2032
- Disease definition
- Methods and sources used for comorbidities of IPF
- Diagnosed prevalent cases of IPF by comorbidity: 2022-2032
- Sources used for drug-treated prevalent cases of IPF
- Number of diagnosed and drug-treated prevalent cases of IPF: 2022-2032
- Key findings
- Current Treatment
- Key findings
- Diagnosis
- Diagnosis of IPF
- Diagnostic tests and criteria
- Diagnostic criteria for IPF
- Comparison of ATS / ERS / JRS / ALAT recommendations for the diagnosis of IPF in 2011, 2018, and 2022
- Expert insight: diagnosis
- Treatment goals
- Key endpoints used in clinical trials for IPF
- Expert Insight: treatment goals of IPF
- Key current therapies
- Overview
- Mechanism of action of current drugs used for IPF
- Current treatments used for IPF
- Market events impacting the use of current therapies in IPF
- Clinical trial outcomes for pirfenidone
- Advantages and disadvantages of pirfenidone
- Key results from select clinical trials investigating pirfenidone for the treatment of IPF
- Recent clinical development of pirfenidone
- Recent trials of pirfenidone in the treatment of IPF
- Expert insight: pirfenidone
- Clinical trial outcomes for nintedanib
- Advantages and disadvantages of nintedanib
- Key results from select clinical trials investigating nintedanib for the treatment of IPF
- Recent clinical development of nintedanib
- Recent trials of nintedanib in the treatment of IPF
- Expert insight: nintedanib
- Clinical trial outcomes for the combination of pirfenidone and nintedanib
- Key results from select clinical trials investigating the combination of pirfenidone and nintedanib for the treatment of IPF
- Key ongoing trials of the combination of pirfenidone and nintedanib in the treatment of IPF
- Expert insight: combination of pirfenidone and nintedanib
- Expert insight: other medications used to treat IPF
- Medical practice
- Overview
- Factors influencing drug selection in IPF
- Treatment providers
- Treatment initiation
- Treatment of severe IPF
- Expert insight: approach to treatment
- Expert insight: the role of specialty centers for IPF
- Generalized treatment decision tree for IPF
- Key findings
- Unmet Need Overview
- Current and future attainment of unmet needs in IPF
- Top unmet needs in IPF: current and future attainment
- Expert insight: unmet need in IPF
- Drug Pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging Therapies
- Key findings
- Key emerging therapies
- Estimated launch dates of key emerging therapies for the treatment of IPF
- Analysis of the clinical development program for treprostinil (inhaled)
- Expert insight: treprostinil (inhaled)
- Expectations for launch and sales opportunity of treprostinil (inhaled) in IPF
- BI-1015550 profile
- Key ongoing trials of BI-1015550 in the treatment of IPF
- Analysis of the clinical development program for BI-1015550
- Expert insight: BI-1015550
- Expectations for launch and sales opportunity of BI-1015550 in IPF
- Key trials of pamrevlumab in the treatment of IPF
- Analysis of the clinical development program for pamrevlumab
- Expectations for launch and sales opportunity of Pamrevlumab in IPF
- PRM-151 profile
- Key results of select clinical trials investigating PRM-151 for the treatment of IPF
- Analysis of the clinical development program for PRM-151
- Expectations for launch and sales opportunity of PRM-151 in IPF
- Early-phase pipeline analysis
- Select compounds in early-phase development for IPF
- Symptomatic or acute therapy in development for IPF
- Select symptomatic or acute therapies in early-phase development for IPF
- Key discontinuations and failures in IPF
- Key discontinuations and failures
- Patient registries
- Patient registries for IPF
- Prominent patient organizations
- Orphan Drug designation
- Key findings
- Access & Reimbursement Overview
- Region-specific reimbursement practices
- Key market access considerations in IPF: United States
- General reimbursement environment: United States
- Key market access considerations in IPF: EU5
- General reimbursement environment: EU5
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- IPF bibliography
- Key Findings
Shreaa, M.B.A., is an associate healthcare and data analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. She conducts secondary and primary market research on U.S. and European biopharmaceutical markets. She holds an M.B.A. in pharmaceutical management from Jamia Hamdard in New Delhi.